Portal de investigación
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ribera, Jordi
- Granada, Isabel
- Morgades, Mireia
- Gonzalez, Teresa
- Ciudad, Juana
- Calasanz, Maria-Jose
- Mercadal, Santiago
- Coll, Rosa
- Gonzalez-Campos, Jose
- Tormo, Mar
- Garcia-Cadenas, Irene
- Gil, Cristina
- Cervera, Marta
- Barba, Pere
- Costa, Dolors
- Ayala, Rosa
- Bermudez, Arancha
- Orfao, Alberto
- Ribera, Josep-Maria
Grupos
Abstract
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged =35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 0007-1048, 1365-2141
- Tipo:
- Article
- Páginas:
- 670-675
- DOI:
- 10.1111/bjh.17844
- PubMed:
- 34549416
- Factor de Impacto:
- 1,677 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRITISH JOURNAL OF HAEMATOLOGY WILEY
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- acute lymphoblastic leukaemia, adults, cytogenetic alterations, prognosis, t(1;19)(q23;p13)/TCF3-PBX1
Campos de Estudio
Cita
Ribera J,Granada I,Morgades M,Gonzalez T,Ciudad J,SUCH E,Calasanz M,Mercadal S,Coll R,Gonzalez J,Tormo M,Garcia I,Gil C,Cervera M,Barba P,Costa D,Ayala R,Bermudez A,Orfao A,Ribera J. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br. J. Haematol. 2021. 196. (3):p. 670-675. IF:8,615. (1).